Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

Data ReadoutpositivePositive

AI Analysis

Summary

Verastem's KRAS inhibitor demonstrated positive efficacy data across three cancer indications: metastatic pancreatic ductal adenocarcinoma, metastatic colorectal cancer, and non-small cell lung cancer, supporting advancement into later-stage studies.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

KRAS inhibitor demonstrated efficacy in mPDAC, mCRC, and NSCLC

Importance:7/10

Sentiment:

0.75

KRAS inhibitoroncologymPDACmCRCNSCLCclinical trial dataPhase advancement

Related Companies

$VSTM

Read the original article

Published by Clinical Trials Arena on October 15, 2026 3:22 PM

Read Original